📰 Response Evaluation News
Response Evaluation News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Response Evaluation. Real-time updates on events, politics, business and more.
February 14, 2024
14.02.2024 - Phase 1b portion of the study expected to be completed within six monthsOCALA, Fla., Feb. 14, 2024 (GLOBE NEWSWIRE) - AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the first subject has been dosed at Erasmus ...
September 13, 2023
A lower dosage of bevacizumab has comparable efficacy to a higher dosage and may reduce toxicity in patients with vestibular schwannomas.
February 24, 2022
/PRNewswire/ -- The Prostate Cancer Foundation (PCF) today announced the 2021 Class of PCF Team Challenge Award recipients and a total of more than $9 million...
February 24, 2022
/PRNewswire/ -- The Prostate Cancer Foundation (PCF) today announced the 2021 Class of PCF Team Challenge Award recipients and a total of more than $9 million...
November 1, 2021
Stereotactic body radiotherapy (SBRT) significantly improved progression- free survival for patients with oligoprogressive, metastatic lung cancer but not breast cancer.
October 26, 2021
Stereotactic body radiation therapy (SBRT) significantly improved progression-free survival in oligoprogressive, metastatic lung cancer, but not breast cancer.
February 9, 2021
COVID-19 First Wave Declined Liver Cancer Care by Angela Mohan on February 9, 2021 at 3:15 PM Liver cancer care has been drastically reduced in the view of first wave of COVID-19. The delays of screening programmes, diagnostic imaging and biopsies, cuts in the numbers of physicians available to treat liver cancer patients, cancellations of surgery, and a drop in the number of patients entered on clinical trials, were just some of the issues reported in the poll. The global L...
January 22, 2021
1 1,2 as a standard of care for intermediate- or poor-risk patients 3 OPDIVO ® (nivolumab) 240 mg (injection for intravenous use) every two weeks or 480 mg every four weeks in combination with CABOMETYX ® (cabozantinib) 40 mg once daily tablets was approved by the U.S. Food and Drug Administration (FDA) for the first-line treatment of patients with advanced renal cell carcinoma (RCC). 1 The approval is based on the Phase 3 CheckMate -9ER trial, which compared OPDIVO in co...